NO20055668L - Beta-amyloidinhibitorer og anvendelse derav - Google Patents

Beta-amyloidinhibitorer og anvendelse derav

Info

Publication number
NO20055668L
NO20055668L NO20055668A NO20055668A NO20055668L NO 20055668 L NO20055668 L NO 20055668L NO 20055668 A NO20055668 A NO 20055668A NO 20055668 A NO20055668 A NO 20055668A NO 20055668 L NO20055668 L NO 20055668L
Authority
NO
Norway
Prior art keywords
beta
amyloid
amyloid inhibitors
dernentia
pugilistica
Prior art date
Application number
NO20055668A
Other languages
English (en)
Other versions
NO20055668D0 (no
Inventor
Luca Barbero
Silvio Traversa
Pierandrea Esposito
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20055668D0 publication Critical patent/NO20055668D0/no
Publication of NO20055668L publication Critical patent/NO20055668L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Navigation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SAMMENDRAG Peptider og derivater eller analoger derav tilveiebringes og som har 1/4-amyloid aggregeringshemmende aktivitet anvendelig i behandlingen og forebyggingen av sykdommer slik som Alzheimers sykdom, Dernentia pugilistica (inkludert hodetraume), arvelig hjerneblødning med amyloidose av den hollandske typen (HCHWA-D) og vaskulær demens med amyloid angiopati.
NO20055668A 2003-04-30 2005-11-30 Beta-amyloidinhibitorer og anvendelse derav NO20055668L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101202 2003-04-30
PCT/EP2004/004807 WO2004096845A2 (en) 2003-04-30 2004-04-29 Beta-amyloid inhibitors and use thereof

Publications (2)

Publication Number Publication Date
NO20055668D0 NO20055668D0 (no) 2005-11-30
NO20055668L true NO20055668L (no) 2005-11-30

Family

ID=33395961

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055668A NO20055668L (no) 2003-04-30 2005-11-30 Beta-amyloidinhibitorer og anvendelse derav

Country Status (7)

Country Link
US (1) US20070293422A1 (no)
EP (1) EP1618129A2 (no)
JP (1) JP2007523848A (no)
AU (1) AU2004234076A1 (no)
CA (1) CA2522460A1 (no)
NO (1) NO20055668L (no)
WO (1) WO2004096845A2 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5190957B2 (ja) * 2006-04-28 2013-04-24 国立大学法人 鹿児島大学 アミロイドβ線維化阻害ペプチド
KR20140058446A (ko) * 2011-05-31 2014-05-14 허치슨 바이오필름 메디컬 솔루션스 리미티드 세포 응집물의 분산 및 분리
KR102475326B1 (ko) * 2022-01-27 2022-12-07 한국기초과학지원연구원 신규한 펩타이드 유사체 및 이를 포함하는 알츠하이머 병 예방 조성물
CN114594272B (zh) * 2022-05-07 2022-08-23 北京第一生物化学药业有限公司 用于检测β-淀粉样蛋白的产品和方法
CN114578066B (zh) * 2022-05-07 2022-08-19 北京第一生物化学药业有限公司 检测β-淀粉样蛋白的产品和方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319498B1 (en) * 1995-03-14 2001-11-20 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US6399584B1 (en) * 1998-03-18 2002-06-04 Institute Curie Pharmaceutical composition containing ezrin mutated on tyrosine 353
GB2346616B (en) * 1998-11-13 2004-04-21 Cyclacel Ltd Transport vectors
US6303576B1 (en) * 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
GB9917724D0 (en) * 1999-07-28 1999-09-29 Medical Res Council Peptides
WO2002062989A2 (en) * 2001-02-08 2002-08-15 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
FR2829940A1 (fr) * 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central

Also Published As

Publication number Publication date
WO2004096845A3 (en) 2005-01-06
CA2522460A1 (en) 2004-11-11
AU2004234076A1 (en) 2004-11-11
EP1618129A2 (en) 2006-01-25
WO2004096845A2 (en) 2004-11-11
NO20055668D0 (no) 2005-11-30
JP2007523848A (ja) 2007-08-23
US20070293422A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20063200L (no) Preparat for forbedring av hud-, har og pelshelse inneholdende flavanoner
NO20055668L (no) Beta-amyloidinhibitorer og anvendelse derav
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20054414L (no) Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
KR960704839A (ko) β-아밀로이드 단백질 생성 억제제(Inhibitors of β-amyloid protein production)
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20053263D0 (no) Hydroksyetylaminderivater for behandling av Alzheimers sykdom.
NO20045281L (no) Tiazolidinoner og anvendelse derav som polo-lignende kinaseinhibitorer
DE60209504D1 (de) Carbocyclische hydrazino-hemmer von kupferhaltigen aminoxidasen
NO20050701L (no) 4-pyrrolidino-fenyl-benzyleter derivater
ATE458753T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
CA2188817A1 (en) Angiogenesis inhibitor
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
DE69233108D1 (de) Hemmstoffe für menschliche neutrophile elastase und menschliches kathepsin g
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
Kida et al. Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
NO20070665L (no) Derivater av 1-fenylalkankarboksylsyrer for behandlingen av neurodegenerative sykdommer
ZA200701798B (en) Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalioproteinases inhibitors
NO20053237L (no) Azapeptider.
NO20065835L (no) Medikamenter som inneholder N-sulfamoyl-N'-arylpiperaziner for profylakse eller behandling av overvekt og beslektede tilstander
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
NO20076405L (no) Anvendelse av 24-nor-UDCA

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application